Ypsomed Holding AG (YPSN) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Ypsomed Holding AG stock CHF 125, price CHF 394, that is 68.3% below the price, quality 65 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.
How to read this chart
60‑month range CHF 119.83 – CHF 430.68 · fair‑value band CHF 97.30 – CHF 203.03 · the CHF 394.40 price screens above the CHF 124.85 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 8, 2026.
Follow Ypsomed Holding in your weekly email
Every Wednesday you see whether Ypsomed Holding is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally.
Show moreShow less
The company offers various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other related services. It offers contract manufacturing of infusion sets and reservoirs.
The company markets its products to hospitals, doctors, pharmacies and patients via subsidiaries and distributors. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Stock analysis
Ypsomed Holding AG (YPSN) currently trades at CHF 394.40, while our model-based Fair Value estimate is CHF 124.85, 68% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of CHF 335.40 per share, and 0 of the 17 models we run sit above the CHF 394.40 price.
Bear case: the Asset-Based group reads lowest at CHF 31.73, and 17 of the 17 models stay below the price. Data coverage for this calculation is high.
Scenario range: CHF 97.30 (bear) to CHF 203.03 (bull), the price of CHF 394.40 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Ypsomed Holding AG reported revenue of CHF 731M in FY2026 versus CHF 465M in FY2022, a compound +12.0%/yr. Reported net income was CHF 222M in FY2026, compounding +76.0%/yr from FY2022. FY2022 was a trough year, so the rate overstates the trend.
Key figures
Market cap CHF 5.4B Mid · P/E ratio 24.1 · P/S ratio 7.34 · EPS (TTM) CHF 16.37 · Dividend yield 1.1% · Net margin 30.4% · Return on equity 31.1% · Return on assets (EBIT) 9.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 88 out of 100 (low confidence).
What moves the price
The share trades about 5% below its 52-week high and 50% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −68%, YPSN screens richer than that median.
Fair Value models
BearCHF 97.30Fair Value CHF 124.85BullCHF 203.03
Price CHF 394.40 · Downside -68.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (CHF 7.24 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.53/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−2.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.6%
Start year 2021 (pandemic). Over 10 years: +8.1% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
≈ +78.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +77.5%
Dividend (yield on the price)1.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 77.4% / 19.1%
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 34%
2026 sits 184% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
⚠ Base effect: the rate starts in the earnings trough around 2021 (starting value 0.93 per share, median 3.90 in 2016 to 2019). It measures the recovery from the trough, not lasting growth.
News mood ⓘNews mood, the average tone of recent news (41 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
AI conclusion: Ypsomed draws strength from solid margins in medical instruments while its main weakness lies in negative free cash flow combined with thin evidence overall.
Main risk: Named competitors such as Becton Dickinson with its Libertas wearable injector and SHL Medical could take customers or force lower prices and margins on Ypsomed's autoinjector and wearable platforms.
Ypsomed is expanding its partnership with ten23 health to include device assembly for the large-volume YpsoDose wearable injector. This integrates another step of the drug-device supply chain for pharma clients seeking simpler access to combination products. Our models see the stock as overvalued. Does this strengthen control over the value chain or tie the company more closely to partner performance?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks
Beats the industry median on 5/14 measures
Overall it trails its industry peers.
Valuation
Quality Score65 · Above median
Fair Value upside−68.3% · Bottom 25%
Profitability
Return on equity (12 months)31.1% · Top 25%
Return on assets16.5% · Top 25%
Net margin (12 months)30.4% · Top 25%
Operating margin (12 months)26.5% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)−13.3% · Bottom 25%
Dividend yield (12 months)1.1% · Below median
Balance sheet
Debt / equity0.15× · Above median
Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper
P/E (12 months)24.1× · Pricier than median
P/B7.17× · Priciest 25%
P/S (12 months)7.34× · Priciest 25%
EV/EBITDA16.7× · Pricier than median
PEG3.21× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 25
FUTURE (revenue growth)0· sector 40
PAST (return on equity)100· sector 31
HEALTH (low debt)93· sector 96
DIVIDEND (yield)22· sector 32
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Ypsomed Holding AG Fair Value". https://www.fairvalue-calculator.com/stock/YPSN
Frequently asked questions
Is Ypsomed Holding AG (YPSN) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of CHF 124.85 versus a price of CHF 394.40, about 68% lower (overvalued).
What is the fair value of YPSN?
Our model-based fair value for Ypsomed Holding AG is CHF 124.85 (as of Nov 8, 2026), built from audited fundamentals. The current price: CHF 394.40.
What is the quality score of YPSN?
Ypsomed Holding AG has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ypsomed Holding AG (YPSN)?
Our model-based price target is the fair value of CHF 124.85 (as of Nov 8, 2026) from 17 valuation models. Cautious scenario CHF 97.30, optimistic scenario CHF 203.03. It is a calculation from audited fundamentals, not an analyst target.
What is the Ypsomed Holding AG stock forecast for 2026?
Our models put fair value at CHF 124.85, about 68% lower versus a price of CHF 394.40 (overvalued). Cautious scenario CHF 97.30, optimistic scenario CHF 203.03. The calculation is refreshed regularly with new filings.
What is the revenue of Ypsomed Holding AG (YPSN)?
Ypsomed Holding AG reported trailing-twelve-month revenue of about CHF 731M (latest available figure, as of Nov 8, 2026).
Does Ypsomed Holding AG pay a dividend?
Ypsomed Holding AG currently shows a dividend yield of 1.12% relative to its recent price (as of Nov 8, 2026).
How much is the dividend of Ypsomed Holding AG (YPSN) and when is the ex-dividend date?
Ypsomed Holding AG pays a dividend of CHF 4.40 per share a year, a dividend yield of 1.1%. The last ex-dividend date was Jul 3, 2026. A dividend has been paid every year since 2008. The payout ratio is 27.0% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Ypsomed Holding AG (YPSN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ypsomed Holding AG it is CHF 124.85 per share (as of Nov 8, 2026), against a price of CHF 394.40. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Ypsomed Holding AG stock overvalued or undervalued in 2026?
As of Nov 8, 2026, YPSN trades above its calculated fair value: price CHF 394.40, fair value CHF 124.85, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of YPSN?
No. The price is what the market pays today (CHF 394.40); the fair value is what the company's own numbers justify (CHF 124.85). For Ypsomed Holding AG the two are CHF 269.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ypsomed Holding AG worth?
The market values Ypsomed Holding AG at about CHF 5.4B (market capitalisation, as of Nov 8, 2026). Per share that is CHF 394.40; our models calculate a fair value of CHF 124.85 per share.
What do the bullish and bearish scenarios say about YPSN?
Our models span a range for Ypsomed Holding AG: cautious scenario CHF 97.30, base CHF 124.85, optimistic CHF 203.03 per share (as of Nov 8, 2026, price CHF 394.40). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of YPSN?
Ypsomed Holding AG trades at a price-to-earnings ratio of 24.1 (as of Nov 8, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of CHF 124.85 is built from several models across several years. Other multiples: PEG 3.2, P/B 7.2, P/S 7.3, EV/EBITDA 16.7.
What is the PEG ratio of YPSN?
The PEG ratio of Ypsomed Holding AG is 3.21 (P/E divided by earnings growth, as of Nov 8, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Ypsomed Holding AG (YPSN)?
Balance-sheet figures for Ypsomed Holding AG (as of Nov 8, 2026): return on equity 31.1%, debt of 0.15 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
How far is YPSN from its 52-week high?
Ypsomed Holding AG trades at CHF 394.40, about 5% below its 52-week high of CHF 413.40 and 50% above the low of CHF 263.74 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of CHF 124.85 is for.
Which stocks are comparable to Ypsomed Holding AG?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ypsomed Holding AG stock attractive at the current price?
The data as of Nov 8, 2026: price CHF 394.40, calculated fair value CHF 124.85 (−68%), Quality Score 65/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of YPSN calculated?
We run Ypsomed Holding AG through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of CHF 124.85 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0% above its aggregate fair value. Ypsomed Holding AG itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ypsomed Holding AG (YPSN)?
The closing price on Nov 6, 2026 was CHF 394.40. Our model-based fair value is CHF 124.85, about 68% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ypsomed Holding AG right now?
The price sits above even our optimistic bull case (CHF 203.03). The favourable scenario is already priced in. Solid but not exceptional quality (65/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (CHF 97.30 to CHF 203.03) leaves room in how you read the outcome.
Where does the earnings growth of Ypsomed Holding AG (YPSN) come from?
Earnings per share at Ypsomed Holding AG grew +15.1 % a year from 2015 to 2026. Broken into its drivers: revenue per share +6.9 %, EBIT margin +6.7 %, tax rate +1.0 %, residual (interest, one-offs) −0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Ypsomed Holding AG
How large is the market capitalisation of Ypsomed Holding AG (YPSN)?
The market capitalisation of Ypsomed Holding AG is CHF 5.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Ypsomed Holding AG (YPSN)?
The price-to-sales ratio of Ypsomed Holding AG is 7.34 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Ypsomed Holding AG (YPSN)?
Earnings per share at Ypsomed Holding AG are CHF 16.37 (price ÷ EPS = P/E 24.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ypsomed Holding AG (YPSN)?
The dividend yield of Ypsomed Holding AG is 1.1% (payout 26.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Ypsomed Holding AG (YPSN)?
The net margin of Ypsomed Holding AG is 30.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Ypsomed Holding AG (YPSN)?
The return on equity (ROE) of Ypsomed Holding AG is 31.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ypsomed Holding AG (YPSN)?
On an EBIT basis the return on assets of Ypsomed Holding AG is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Ypsomed Holding AG (YPSN)?
The operating margin of Ypsomed Holding AG is 26.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Ypsomed Holding AG (YPSN)?
Revenue at Ypsomed Holding AG is growing −13.3% versus a year earlier (3y avg +13.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Ypsomed Holding AG (YPSN)?
Earnings per share at Ypsomed Holding AG are growing +51.7% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Ypsomed Holding AG (YPSN) generate?
The free cash flow of Ypsomed Holding AG is −CHF 16.3M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Ypsomed Holding AG (YPSN) carry?
The net debt of Ypsomed Holding AG is CHF 232M (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Ypsomed Holding AG in the live analysis
One click puts Ypsomed Holding AG on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 8, 2026